Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission.
In 1994, hepatitis C virus (HCV) infection was transmitted to four HIV seropositive patients attending the Department of Angiology, University Clinics, Frankfurt am Main, by the administration of Gammagard. The patients were suffering from thrombocytopenia and received betweeen 20 and 30 g of the contaminated lot 93F21AB11. GBV-C/HGV RNA could be amplified from the Gammagard lot 93F21AB11 using 5'NCR and NS5 primer pairs. All the four patients were negative in the GBV-C/HGV RT-PCR prior to therapy and until the end of the follow-up period. GBV-C/HGV IgG antibodies to the putative envelope (E2) were detected using the E2 HGV-env kit (Boehringer-Mannheim, Germany) in Gammagard lot 93F21AB11 and in one patient before donation of immunoglobulin. Anti-E2 seroconversion was observed in one recipient, the other two patients remained anti-E2 seronegative until the end of the observation period. It is concluded that there is no direct evidence for transmission of GBV-C/HGV by contaminated intravenous immunoglobulin since GBV-C/HGV RNA was not detected in the recipients up to 1 year after administration.
Berger
A
A
Institut für Medizinische Virologie im Zentrum der Hygiene, Universitätskliniken Frankfurt, Frankfurt/Main, Germany.
Doerr
H W
HW
Scharrer
I
I
Weber
B
B
D000328:Adult; D000361:Agammaglobulinemia / Q000209:etiology / Q000628:therapy; D001483:Base Sequence; D017931:DNA Primers / Q000235:genetics; D004340:Drug Contamination; D005260:Female; D018067:Flaviviridae / Q000235:genetics / Q000302:isolation & purification*; D015658:HIV Infections / Q000150:complications / Q000628:therapy*; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000635:transmission* / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000635:transmission; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D008297:Male; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy
D017931:DNA Primers; D016756:Immunoglobulins, Intravenous; D012367:RNA, Viral